Kura Oncology to Participate in Four Upcoming Investor Conferences

Rhea-AI Summary

Kura Oncology, a clinical-stage biopharmaceutical company, announced that its CEO, Troy Wilson, will participate in four virtual investor conferences in February and March 2021. Key events include a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, a panel discussion at the Cowen 41st Annual Health Care Conference on March 3, and a presentation at the Barclays Virtual Global Healthcare Conference on March 10. Kura's drug candidates, including tipifarnib and KO-539, target specific cancer signaling pathways to enhance treatment outcomes.

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive officer is scheduled to participate in four upcoming virtual investor conferences:

• A fireside chat at the SVB Leerink 10^th Annual Global Healthcare Conference at 2:20 p.m. ET / 11:20 a.m. PT on February 25, 2021;
  
  
• A leukemias panel discussion at the Cowen 41^st Annual Health Care Conference at 11:40 a.m. ET / 8:40 a.m. PT on March 3, 2021;
  
  
• A pre-recorded fireside chat at the H.C Wainwright Global Life Sciences Conference available on-demand starting at 7:00 a.m. ET / 4:00 a.m. PT on March 9, 2021; and
  
  
• A company presentation at the Barclays Virtual Global Healthcare Conference on March 10, 2021 at 4:10 p.m. ET / 1:10 p.m. PT.
  

Live audio webcasts of the SVB Leerink and Barclays events will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available for 30 days following the events.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company’s pipeline is also highlighted by KO-539, a potent and selective menin inhibitor currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed/refractory acute myeloid leukemia. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

 

FAQ

What events is Kura Oncology participating in February and March 2021?

Kura Oncology will participate in four virtual investor conferences: SVB Leerink Annual Global Healthcare Conference on February 25, Cowen Health Care Conference on March 3, H.C. Wainwright Global Life Sciences Conference on March 9, and Barclays Virtual Global Healthcare Conference on March 10.

Who is participating in the upcoming Kura Oncology investor conferences?

Troy Wilson, Ph.D., J.D., the President and CEO of Kura Oncology, will participate in the upcoming investor conferences.

How can I access the Kura Oncology conference webcasts?

Live webcasts of the SVB Leerink and Barclays events will be available on Kura Oncology's website, with archived replays for 30 days post-event.

What is Kura Oncology's most advanced drug candidate?

Kura Oncology's most advanced drug candidate is tipifarnib, used in a trial for HRAS mutant head and neck squamous cell carcinoma.

What is KO-539 and its current clinical status?

KO-539 is a potent menin inhibitor currently in a Phase 1/2A clinical trial (KOMET-001) for relapsed/refractory acute myeloid leukemia.